EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production

Given US FDA’s strict requirements for generic combination products, brand competitors to Mylan’s pricey epinephrine auto-injector such as kaléo’s Auvi-Q might be the best that buyers can expect for a while.

Manufacturing checks and balances give kaleo Inc. great confidence in the reliability of its Auvi-Q epinephrine auto-injector, which it plans to relaunch in the US on Feb. 14 after reacquiring rights from Sanofi and retooling production.

Auvi-Q is coming back on the market with some fanfare – the exact opposite of the way it limped off....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet